# US 2014/0155368 A1 · Combination pharmaceuticals and methods thereof using proteinacious channels as treatments for medical conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155368 A1
- Document ID: US20140155368A1
- Status: Published application
- Kind: A1
- Application number: 14/174,902
- Filed: 2014-02-07
- Published: 2014-06-05
- Earliest claimed: 2009-10-30
- Assignees: Loyola University of Chicago
- Applicants: Loyola University Chicago
- Inventors: Kenneth L. Byron
- Web page: https://patentgrep.com/patent/US20140155368A1

## CPC

- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/27: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A61K 31/415: 1,2-Diazoles
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- G01N 33/5038: {involving detection of metabolites per se}
- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- G01N 2800/122: Chronic or obstructive airway disorders, e.g. asthma COPD
- G01N 2800/32: Cardiovascular disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods and combination pharmaceuticals for treating bronchospastic medical conditions by utilizing the electrophysiology of proteinacious channels in lipid membranes of mammalian cells. The combination pharmaceuticals include at least one β-adrenergic receptor agonist, and at least one composition adapted to effect the electrophysiology of Kv7 potassium channels of a lipid membrane of an airway smooth muscle cell. The pharmaceutical may be administered to a living body in a therapeutic amount sufficient to activate the Kv7 potassium channels of an airway smooth muscle cell.

## Claims

### Claim 1

A combination pharmaceutical comprising:
at least one β-adrenergic receptor agonist; and
at least one composition adapted to effect the electrophysiology of Kv7 potassium channels of a lipid membrane of an airway smooth muscle cell.

### Claim 2 (depends on 1)

The combination pharmaceutical of claim 1, wherein the effect of the composition is to activate the Kv7 potassium channels.

### Claim 3 (depends on 1)

The combination pharmaceutical of claim 1, wherein the composition is chosen from the group consisting of retigabine, zinc pyrithione, or a celecoxib analog.

### Claim 4 (depends on 1)

The combination pharmaceutical of claim 1, wherein the β-adrenergic receptor agonist is formoterol.

### Claim 5 (depends on 1)

A method of treating a bronchospastic condition that can lead to airway obstruction in a living body, the method comprising administering the combination pharmaceutical of claim 1 to the living body in a therapeutic amount sufficient to activate the Kv7 potassium channels of an airway smooth muscle cell.

### Claim 6 (depends on 5)

The method of claim 5, wherein the bronchospastic condition is an asthmatic condition.

### Claim 7 (depends on 5)

The method of claim 5, wherein the airway smooth muscle cell is in a wall of a bronchiole of a lung.

### Claim 8 (depends on 5)

The method of claim 5, wherein the pharmaceutical is administered to the living body as an inhalant.

### Claim 9

A method of treating a bronchospastic condition that can lead to airway obstruction in a living body, the method comprising administering a pharmaceutical to the living body in a therapeutic amount sufficient to activate the Kv7 potassium channels of an airway smooth muscle cell.

### Claim 10 (depends on 9)

The method of claim 9, wherein the pharmaceutical is administered to the living body as an inhalant.

### Claim 11 (depends on 9)

The method of claim 9, wherein the bronchospastic condition is an asthmatic condition.

### Claim 12 (depends on 9)

The method of claim 9, wherein the pharmaceutical comprises a composition chosen from the group consisting of retigabine, zinc pyrithione, or a celecoxib analog.

### Claim 13 (depends on 9)

The method of claim 9, wherein the airway smooth muscle cell is in a wall of a bronchiole of a lung.

### Claim 14 (depends on 9)

The method of claim 9, further comprising administering a second pharmaceutical comprising a β-adrenergic receptor agonist to the living body.

### Claim 15 (depends on 14)

The method of claim 14, wherein the β-adrenergic receptor agonist is formoterol.

### Claim 16 (depends on 9)

The method of claim 9, wherein the pharmaceutical further comprises a β-adrenergic receptor agonist.

### Claim 17 (depends on 16)

The method of claim 16, wherein the β-adrenergic receptor agonist is formoterol.